Chemotherapy Market Research Report: Information By Drug Class (Mitotic Inhibitors, Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors and Antitumor Antibiotic), By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Leukemia and Ovarian Cancer), By Route of Drug Administration (Intravenous, Oral, Subcutaneous, Intra-Muscular, Intravesicular, Topical, Intraperitoneal and Intraventricular/Intrathecal) and By End-User (Specialty Centers and Hospitals & Clinics), and By Region (North

1 Market Introduction

1.1 Definition 13

1.2 Scope of the Study 13

1.3 Market Structure 13

2 Research Methodology

2.1 Research Process 14

2.2 Primary Research 15

2.3 Secondary Research 16

2.4 Market Size Estimation 17

2.5 Forecast Model 17

4 Market Dynamics

3.1 Introduction 18

3.2 Drivers 19

3.2.1 Increasing Prevalence of Cancer 19

3.2.2 Increasing Expenditure on Oncology Medicine and Research 19

3.2.3 Reimbursements and Growing Health Insurance 19

3.3 Restraints 20

3.3.1 High Cost of Treatment 20

3.3.2 Side-Effects of Chemotherapy 20

3.4 Opportunities 20

3.4.1 Entering Developing Economies 20

5 Market Factor Analysis

4.1 Value Chain Analysis 21

4.1.1 R&D and Designing 21

4.1.2 Manufacturing 21

4.1.3 Distribution & Sales 21

4.1.4 Post-Sales Review 22

4.2 Porter’s Five Forces Model 23

4.2.1 Bargaining Power of Suppliers 24

4.2.2 Bargaining Power of Buyers 24

4.2.3 Threat of New Entrants 24

4.2.4 Threat of Substitutes 24

4.2.5 Intensity of Rivalry 24

4.3 Investment Opportunities Analysis 25

4.4 Pricing Analysis 25

4.5 Chemotherapy Drugs by Route of Administration 26

4.6 Chemotherapy Drugs by Indication 27

6 Global Chemotherapy Market, by Drug Class

5.1 Introduction 28

5.2 Alkylating agents 29

5.3 Mitotic inhibitors 30

5.4 Antimetabolites 30

5.5 Topoisomerase Inhibitors 30

5.6 Antitumor antibiotic 31

7 Global Chemotherapy Market, by Indication

6.1 Introduction 32

6.2 Lung Cancer 33

6.3 Breast Cancer 34

6.4 Colorectal Cancer 34

6.5 Prostate Cancer 34

6.6 Stomach Cancer 35

6.7 Lymphoma 35

6.8 Leukemia 35

6.9 Ovarian Cancer 36

8 Global Chemotherapy Market, by Route of Administration

7.1 Intravenous 39

7.2 Oral 39

7.3 Subcutaneous 39

7.4 Intra-Muscular 40

7.5 Intravesicular 40

7.6 Topical 40

7.7 Intraperitoneal 41

7.8 Intraventricular/Intrathecal 41

9 Global Chemotherapy Market, by End User

8.1 Introduction 42

8.2 Specialty Centers 43

8.3 Hospitals & Clinics 43

10 Global Chemotherapy Market, by Region

9.1 Introduction 44

9.2 Americas 46

9.2.1 North America 48

9.2.1.1 US 51

9.2.1.2 Canada 53

9.2.2 South America 55

9.3 Europe 57

9.3.1 Western Europe 59

9.3.1.1 Germany 62

9.3.1.2 France 64

9.3.1.3 UK 66

9.3.1.4 Italy 68

9.3.1.5 Spain 70

9.3.1.6 Rest of Western Europe 72

9.3.2 Eastern Europe 74

9.4 Asia-Pacific 76

9.4.1 Japan 79

9.4.2 China 81

9.4.3 India 83

9.4.4 Australia 85

9.4.5 South Korea 87

9.4.6 Rest of Asia-Pacific 89

9.5 Middle East & Africa 91

9.5.1 Middle East 93

9.5.2 Africa 95

11 Competitive Landscape

10.1 Company Share Analysis 98

12 Company Profiles

11.1 Johnson & Johnson Services Inc. 100

11.1.1 Company Overview 100

11.1.2 Financial Overview 100

11.1.3 Products/Services Offered 101

11.1.4 Key Developments 101

11.1.5 SWOT Analysis 101

11.1.6 Key Strategies 102

11.2 GlaxoSmithKline PLC 103

11.2.1 Company Overview 103

11.2.2 Financial Overview 103

11.2.3 Products/Services Offered 104

11.2.4 Key Developments 104

11.2.5 SWOT Analysis 104

11.2.6 Key Strategies 104

11.3 Eli Lilly and Company 105

11.3.1 Company Overview 105

11.3.2 Financial Overview 105

11.3.3 Products/Services Offered 106

11.3.4 Key Developments 106

11.3.5 SWOT Analysis 106

11.3.6 Key Strategies 106

11.4 F. Hoffmann-La Roche Ltd 107

11.4.1 Company Overview 107

11.4.2 Financial Overview 107

11.4.3 Products/Services Offered 108

11.4.4 Key Developments 108

11.4.5 SWOT Analysis 108

11.4.6 Key Strategies 109

11.5 Novartis AG 110

11.5.1 Company Overview 110

11.5.2 Financial Overview 110

11.5.3 Products/Services Offered 111

11.5.4 Key Developments 111

11.5.5 SWOT Analysis 111

11.5.6 Key Strategies 111

11.6 Pfizer Inc. 112

11.6.1 Company Overview 112

11.6.2 Financial Overview 112

11.6.3 Products/Services Offered 113

11.6.4 Key Developments 113

11.6.5 SWOT Analysis 113

11.6.6 Key Strategies 113

11.7 Merck & Co. Inc. 114

11.7.1 Company Overview 114

11.7.2 Financial Overview 114

11.7.3 Products/Services Offered 115

11.7.4 Key Developments 115

11.7.5 SWOT Analysis 115

11.7.6 Key Strategies 115

11.8 Sanofi S.A. 116

11.8.1 Company Overview 116

11.8.2 Financial Overview 116

11.8.3 Products/Services Offered 117

11.8.4 Key Developments 117

11.8.5 SWOT Analysis 118

11.8.6 Key Strategies 118

11.9 Celgene Corporation 119

11.9.1 Company Overview 119

11.9.2 Financial Overview 119

11.9.3 Products/Services Offered 120

11.9.4 Key Developments 120

11.9.5 SWOT Analysis 120

11.9.6 Key Strategies 121

11.10 Bristol-Myers Squibb Company 122

11.10.1 Company Overview 122

11.10.2 Financial Overview 122

11.10.3 Products/Services Offered 123

11.10.4 Key Developments 123

11.10.5 SWOT Analysis 123

11.10.6 Key Strategies 124

13 Appendix

12.1 References 125

12.2 Related Reports 125

14 List of Tables

TABLE 1 GLOBAL CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 29

TABLE 2 GLOBAL CHEMOTHERAPY MARKET FOR ALKYLATING AGENTS, BY REGION, 2020–2027 (USD MILLION) 29

TABLE 3 GLOBAL CHEMOTHERAPY MARKET FOR MITOTIC INHIBITORS, BY REGION, 2020–2027 (USD MILLION) 30

TABLE 4 GLOBAL CHEMOTHERAPY MARKET FOR ANTIMETABOLITES, BY REGION, 2020–2027 (USD MILLION) 30

TABLE 5 GLOBAL CHEMOTHERAPY MARKET FOR TOPOISOMERASE INHIBITORS, BY REGION, 2020–2027 (USD MILLION) 30

TABLE 6 GLOBAL CHEMOTHERAPY MARKET FOR ANTITUMOR ANTIBIOTIC, BY REGION, 2020–2027 (USD MILLION) 31

TABLE 7 GLOBAL CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 33

TABLE 8 GLOBAL CHEMOTHERAPY MARKET FOR LUNG CANCER, BY REGION, 2020–2027 (USD MILLION) 33

TABLE 9 GLOBAL CHEMOTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 10 GLOBAL CHEMOTHERAPY MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 11 GLOBAL CHEMOTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 12 GLOBAL CHEMOTHERAPY MARKET FOR STOMACH CANCER, BY REGION, 2020–2027 (USD MILLION) 35

TABLE 13 GLOBAL CHEMOTHERAPY MARKET FOR LYMPHOMA, BY REGION, 2020–2027 (USD MILLION) 35

TABLE 14 GLOBAL CHEMOTHERAPY MARKET FOR LEUKEMIA, BY REGION, 2020–2027 (USD MILLION) 35

TABLE 15 GLOBAL CHEMOTHERAPY MARKET FOR OVARIAN CANCER, BY REGION, 2020–2027 (USD MILLION) 36

TABLE 16 GLOBAL CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 38

TABLE 17 GLOBAL CHEMOTHERAPY MARKET FOR INTRAVENOUS, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 18 GLOBAL CHEMOTHERAPY MARKET FOR ORAL, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 19 GLOBAL CHEMOTHERAPY MARKET FOR SUBCUTANEOUS, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 20 GLOBAL CHEMOTHERAPY MARKET FOR INTRA-MUSCULAR, BY REGION, 2020–2027 (USD MILLION) 40

TABLE 21 GLOBAL CHEMOTHERAPY MARKET FOR INTRAVESICULAR, BY REGION, 2020–2027 (USD MILLION) 40

TABLE 22 GLOBAL CHEMOTHERAPY MARKET FOR TOPICAL, BY REGION, 2020–2027 (USD MILLION) 40

TABLE 23 GLOBAL CHEMOTHERAPY MARKET FOR INTRAPERITONEAL, BY REGION, 2020–2027 (USD MILLION) 41

TABLE 24 GLOBAL CHEMOTHERAPY MARKET FOR INTRAVENTRICULAR/INTRATHECAL, BY REGION, 2020–2027 (USD MILLION) 41

TABLE 25 GLOBAL CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 43

TABLE 26 GLOBAL CHEMOTHERAPY MARKET FOR SPECIALITY CENTERS, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 27 GLOBAL CHEMOTHERAPY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 28 GLOBAL CHEMOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 45

TABLE 29 AMERICAS: CHEMOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 30 AMERICAS: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 46

TABLE 31 AMERICAS: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 47

TABLE 32 AMERICAS: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 47

TABLE 33 AMERICAS: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 48

TABLE 34 NORTH AMERICA: CHEMOTHERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 48

TABLE 35 NORTH AMERICA: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 49

TABLE 36 NORTH AMERICA: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 49

TABLE 37 NORTH AMERICA: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 50

TABLE 38 NORTH AMERICA: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 50

TABLE 39 US: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 51

TABLE 40 US: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 51

TABLE 41 US: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 52

TABLE 42 US: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 52

TABLE 43 CANADA: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 53

TABLE 44 CANADA: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 53

TABLE 45 CANADA: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 54

TABLE 46 CANADA: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 54

TABLE 47 SOUTH AMERICA: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 55

TABLE 48 SOUTH AMERICA: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 55

TABLE 49 SOUTH AMERICA: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 56

TABLE 50 SOUTH AMERICA: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 56

TABLE 51 EUROPE: CHEMOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 57

TABLE 52 EUROPE: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 57

TABLE 53 EUROPE: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 58

TABLE 54 EUROPE: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 58

TABLE 55 EUROPE: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 59

TABLE 56 WESTERN EUROPE: CHEMOTHERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59

TABLE 57 WESTERN EUROPE: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 60

TABLE 58 WESTERN EUROPE: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 60

TABLE 59 WESTERN EUROPE: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 61

TABLE 60 WESTERN EUROPE: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 61

TABLE 61 GERMANY: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 62

TABLE 62 GERMANY: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 62

TABLE 63 GERMANY: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 63

TABLE 64 GERMANY: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 63

TABLE 65 FRANCE: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 64

TABLE 66 FRANCE: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 64

TABLE 67 FRANCE: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 65

TABLE 68 FRANCE: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 65

TABLE 69 UK: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 66

TABLE 70 UK: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 66

TABLE 71 UK: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 67

TABLE 72 UK: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 67

TABLE 73 ITALY: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 68

TABLE 74 ITALY: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 68

TABLE 75 ITALY: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 69

TABLE 76 ITALY: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 69

TABLE 77 SPAIN: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 70

TABLE 78 SPAIN: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 70

TABLE 79 SPAIN: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 71

TABLE 80 SPAIN: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 71

TABLE 81 REST OF WESTERN EUROPE: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 72

TABLE 82 REST OF WESTERN EUROPE: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 72

TABLE 83 REST OF WESTERN EUROPE: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 73

TABLE 84 REST OF WESTERN EUROPE: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 73

TABLE 85 EASTERN EUROPE: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 74

TABLE 86 EASTERN EUROPE: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 74

TABLE 87 EASTERN EUROPE: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 75

TABLE 88 EASTERN EUROPE: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 75

TABLE 89 ASIA-PACIFIC: CHEMOTHERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 76

TABLE 90 ASIA-PACIFIC: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 77

TABLE 91 ASIA-PACIFIC: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 77

TABLE 92 ASIA-PACIFIC: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 78

TABLE 93 ASIA-PACIFIC: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 78

TABLE 94 JAPAN: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 79

TABLE 95 JAPAN: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 79

TABLE 96 JAPAN: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 80

TABLE 97 JAPAN: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 80

TABLE 98 CHINA: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 81

TABLE 99 CHINA: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 81

TABLE 100 CHINA: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 82

TABLE 101 CHINA: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 82

TABLE 102 INDIA: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 83

TABLE 103 INDIA: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 83

TABLE 104 INDIA: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 84

TABLE 105 INDIA: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 84

TABLE 106 AUSTRALIA: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 85

TABLE 107 AUSTRALIA: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 85

TABLE 108 AUSTRALIA: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 86

TABLE 109 AUSTRALIA: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 86

TABLE 110 SOUTH KOREA: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 87

TABLE 111 SOUTH KOREA: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 87

TABLE 112 SOUTH KOREA: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 88

TABLE 113 SOUTH KOREA: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 88

TABLE 114 REST OF ASIA-PACIFIC: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 89

TABLE 115 REST OF ASIA-PACIFIC: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 89

TABLE 116 REST OF ASIA-PACIFIC: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 90

TABLE 117 REST OF ASIA-PACIFIC: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 90

TABLE 118 MIDDLE EAST & AFRICA: CHEMOTHERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 91

TABLE 119 MIDDLE EAST & AFRICA: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 91

TABLE 120 MIDDLE EAST & AFRICA: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 92

TABLE 121 MIDDLE EAST & AFRICA: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 92

TABLE 122 MIDDLE EAST & AFRICA: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 93

TABLE 123 MIDDLE EAST: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 93

TABLE 124 MIDDLE EAST: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 94

TABLE 125 MIDDLE EAST: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 94

TABLE 126 MIDDLE EAST: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 95

TABLE 127 AFRICA: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 95

TABLE 128 AFRICA: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 96

TABLE 129 AFRICA: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 96

TABLE 130 DAFRICA: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 97

15 List of Figures

FIGURE 1 GLOBAL CHEMOTHERAPY MARKET: MARKET STRUCTURE 13

FIGURE 2 RESEARCH PROCESS OF MRFR 14

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 17

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL CHEMOTHERAPY MARKET 18

FIGURE 5 VALUE CHAIN: GLOBAL CHEMOTHERAPY MARKET 21

FIGURE 6 PORTER’S FIVE FORCES ANALYSIS: GLOBAL CHEMOTHERAPY MARKET 23

FIGURE 7 GLOBAL CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020 & 2027 (USD MILLION) 28

FIGURE 8 GLOBAL CHEMOTHERAPY MARKET, BY INDICATION, 2020 & 2027 (USD MILLION) 32

FIGURE 9 GLOBAL CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020 & 2027 (USD MILLION) 38

FIGURE 10 GLOBAL CHEMOTHERAPY MARKET, BY END USER, 2020 & 2027 (USD MILLION) 42

FIGURE 11 GLOBAL CHEMOTHERAPY MARKET, BY REGION, 2020 & 2027 (USD MILLION) 45

FIGURE 12 AMERICAS: CHEMOTHERAPY MARKET SHARE, BY REGION, 2020 (%) 46

FIGURE 13 NORTH AMERICA: CHEMOTHERAPY MARKET SHARE, BY COUNTRY, 2020 (%) 48

FIGURE 14 EUROPE: CHEMOTHERAPY MARKET SHARE, BY REGION, 2020 (%) 57

FIGURE 15 WESTERN EUROPE: CHEMOTHERAPY MARKET SHARE, BY COUNTRY, 2020 (%) 59

FIGURE 16 ASIA-PACIFIC: CHEMOTHERAPY MARKET SHARE, BY COUNTRY, 2020 (%) 76

FIGURE 17 MIDDLE EAST & AFRICA: CHEMOTHERAPY MARKET SHARE, BY REGION, 2020 (%) 91

FIGURE 18 GLOBAL CHEMOTHERAPY MARKET, COMPANY SHARE ANALYSIS, 2020 98